Press Releases Ypsomed Group

Burgdorf – Ypsomed increased sales by CHF 45.3 million in the first half year of 2018/19. The operating result (EBIT) amounts to CHF 68.4 million. The result includes a CHF 49.8 million compensation from Insulet Corp. in terms of revenue and profit. The growth strategies with own products in expansion, innovation and production will be continued with determination. The mylife YpsoPump insulin pump is developing successfully above expectations.

Press Releases Ypsomed Group

Burgdorf – In the business year 2017/18, Ypsomed generated consolidated sales of CHF 466.1 million (prior year: CHF 389.6 million). Compared with the previous year, this represents an increase in sales of 19.7%. The operating results (EBIT) increased by 10.4% compared to the previous year, from CHF 55.3 million to CHF 61.1 million. Net profit increased to CHF 52.1 million (previous year: CHF 46.2 million).

Press Releases Ypsomed Group

Burgdorf - The guidance of CHF 60 million EBIT for the 2017/18 financial year announced in November 2017 remains unchanged. Ypsomed is investing in its global expansion and the establishment of new subsidiaries for the insulin pump business. Ypsomed expects sustained growth in the Ypsomed Delivery Systems (YDS) segment.

Press Releases Ypsomed Group

Burgdorf - During the first six months of the business year 2017/18, Ypsomed generated a consolidated total turnover of CHF 213.4 million. The growth corresponds to an increase in turnover of 15.1% (previous year: CHF 185.4 million). The net profit for the reporting period amounts to CHF 23.4 million (previous year CHF 22.4 million). The operating result amounts to CHF 26.9 million with an EBIT margin of 12.9 %. Ypsomed expects a growth in turnover of approximately 18% versus the presently forecast 15% and increases the forecast to an operating result of around CHF 60 million for the business year 2017/18.

Press Releases Ypsomed Group

Burgdorf – Hanmi Pharmaceutical Co., Ltd. has three biotechnology proteins in its project portfolio that are in various stages of development and approval.